Abstract: Mesoporous silica nanoparticles (MSNs) that may be useful as ultrasound contrast agents for detecting and treating bladder cancer are described herein. The MSNs include a lanthanide, a fluorophore, and an agent detectable by ultrasound.

Abstract: The present invention relates to a somatostatin analogue composition for radiopharmaceutical use, in particular for diagnostic or therapeutic use. More specifically the somatostatin analogue is a receptor-selective somatostatin peptide antagonist.

Abstract: A brachytherapy device including a base adapted for being at least partially introduced into a body of a subject and a plurality of radionuclide atoms of a first alpha-emitting isotope, coupled to the base in a manner that not more than 15% of the radionuclide atoms leave the base in 24 hours, in methods other than radioactive decay. When installed in a human subject, the brachytherapy device emits radionuclide atoms of the first alpha-emitting isotope at a rate of at least 0.1% of the number of radionuclide atoms of the first alpha-emitting isotope coupled to the base, per 24 hours.

Abstract: The disclosed technology provides improved adhesive composition of use with dentures. These improved compositions include (a) a cross linked poly(acrylic) acid polymer, in combination with (b) a carbomethylcellulose (CMC) component and/or (c) an adherence promoting component. The compositions balance the many competing goals for effective denture adhesives, including adhesive strength and dispensing viscosity, without the need for zinc.

Abstract: A non-cellular dental tissue regeneration promoting kit is provided that makes effective dental tissue regeneration possible without transplantation of autologous or allogeneic stem cells or components derived from stem cells. The kit comprises: a pretreatment agent comprising a serine protease; and a non-cellular root canal filling material, the non-cellular root canal filling material comprising: a regeneration promoting compound including at least one of a CCR3 antagonist, a CCL11 neutralizing antibody, and an ALK5 inhibitor; and an extracellular matrix. The kit is preferably used for middle-aged or elderly individuals.

Abstract: The invention relates to a kit of parts for preparing a glass ionomer composition for dental use, the kit comprising a Paste A and a Paste B, Paste A comprising water, acid-reactive inorganic filler A, non acid-reactive filler B1, sugar alcohol with 6 hydroxyl moieties, Paste B comprising water, polyacid, non acid-reactive filler B2, the sugar alcohol being present in an amount of not more than 2 wt. % and the water being present in an amount of not more than 15 wt. %, wt. % with respect to the whole composition obtained when mixing Paste A and Paste B. The invention also relates to a hardened glass ionomer composition for dental use obtained by mixing Paste A and Paste B of the kit of parts.

Abstract: A personal care cosmetic composition; its method of manufacture; and its method of use are disclosed.

Abstract: A hair conditioner composition comprising: a) a fatty acid; b) a fatty alcohol; and c) an antimicrobial system comprising: i) glyceryl caprylate; and ii) one or more of 4-hydroxyacetophenone and pentylene glycol.

Abstract: Disclosed are controlled release particles, each controlled release particle of which includes: (a) a core including at least one hydrophobic active material and an emulsifier which is an oil-soluble or oil-dispersible lecithin emulsifier; and (b) a wall at least partially surrounding the core and including an acid insoluble polymer, a colloidal silica, a water insoluble divalent salt, a film forming polymer, and optionally a powder flow aid, wherein the controlled release particle is configured to retain the at least one hydrophobic active material when exposed to an acidic aqueous solution with a pH less than 6, and to release the at least one hydrophobic active material when exposed to a basic aqueous solution with a pH greater than 7. A method for preparing the particles and compositions containing the particles are also disclosed.

Abstract: The present application relates to a composition comprising at least one neutralizing agent, at least one stabilizing agent, at least three chelator agents and at least one cationic agent. Also, the present invention is related to a method for manufacturing the composition, a method for applying the composition onto keratin fibers for shaping or altering the shape of the keratin fibers, particularly hair, a kit that is suitable for performing the claimed method for shaping or altering the shape of the hair and the use of the claimed composition for shaping or altering the shape of the hair.

Abstract: The invention relates to a process for preparing an opaque composition using ethylene glycol distearate.

Abstract: The non-therapeutic, cosmetic, oral use of a composition as an active ingredient for whitening and/or lightening the skin and/or depigmenting the skin, in particular for reducing the size of brown spots, including at least cystine and glutathione in a cystine/glutathione ratio ranging from 1.5 to 4, the composition advantageously further comprising glycine and/or glutamine Preferably, the composition also includes at least one component selected from the group formed by zinc or one of its salts, copper or one of its salts, selenium or one of its salts, vitamins B, in particular B3, B5, B6 and/or B8, vitamin E, melon juice extracts, horsetail extracts and mixtures of these components.

Abstract: 1.

Abstract: An anhydrous personal care composition, comprising: (a) 45 to 60 weight % of at least one ester, selected from (i) triglycerides, (ii) diglycerides, (iii) monoglycerides, (iv) monoesters of diols, and (v) diesters of diols; (b) a first wax having a melting point of from 35° C. to 72° C. present in an amount of 5 to 25 weight %; (c) a second wax having a melting point of 73 to 90° C. present in an amount of 0.5 to 15 weight %; and (d) at least one plant oil having a saponification value of from 150 to 275 mg KOH/g present in an amount of 5 to 35 weight.

Abstract: The invention relates to a method for producing an extract of seeds of the Entada genus by selective hydrolysis of the metabolites accumulated in the seeds. The invention also relates to the extract produced using such a method, to a composition comprising such an extract, and to the cosmetic and dermocosmetic applications of such an extract.

Abstract: Described herein are compositions useful for moisturizing and/or improving the appearance of skin by evening skin tone and/or reducing the appearance of dark spots or hyperpigmentation. The compositions comprise cosmetic ingredients such as lactobacillus ferment; Ferula foetida root extract; Helianthus annuus (sunflower) seed extract; Terminalia ferdinandiana fruit extract, and niacinamide.

Abstract: In one aspect, the present disclosure provides for novel compositions of matter comprising multi domain peptide (MDP) hydrogels and cyclic dinucleotides (CDNs). Also disclosed are method of using such compositions in the treatment of cancer, including in particular the treatment of head and neck cancers, such as those resistant to CDN therapy.

Abstract: The present technology relates to depots for the treatment of postoperative pain via sustained, controlled release of a therapeutic agent. In some embodiments, the depot may comprise a therapeutic region comprising an analgesic, and a control region comprising a bioresorbable polymer and a releasing agent mixed with the polymer. The releasing agent may be configured to dissolve when the depot is placed in vivo to form diffusion openings in the control region. The depot may be configured to be implanted at a treatment site in vivo and, while implanted, release the therapeutic agent at the treatment site for no less than 3 days.

Abstract: Disclosed herein are compositions and methods for the treatment of otic disorders with immunomodulating agents and auris pressure modulators. In these methods, the auris compositions and formulations are administered locally to an individual afflicted with an otic disorder, through direct application of the immunomodulating and/or auris pressure modulating compositions and formulations onto the auris media and/or auris interna target areas, or via perfusion into the auris media and/or auris interna structures.

Abstract: A composition configured for oral use is provided, the composition including a filler in an amount of at least 20% by weight, based on the total weight of the composition, and at least one active ingredient including one or more botanical materials, stimulants, amino acids, vitamins, antioxidants, cannabinoids, pharmaceutical agents, or a combination thereof. The composition further includes a salt and at least one sweetener. The composition has a moisture content of at least about 40% by weight, based on the total weight of the composition.

Abstract: A Methotrexate composition for oral administration is provided comprising a pharmaceutically acceptable salt of Methotrexate and an aqueous carrier agent. The Methotrexate salt is substantially or completely soluble in the aqueous carrier agent, forming an aqueous solution. There is also provided a method of manufacturing a Methotrexate composition for oral administration, comprising mixing a pharmaceutically acceptable salt of Methotrexate with an aqueous carrier agent until the Methotrexate salt is substantially or completely soluble in the carrier agent to form an aqueous solution.

Abstract: Disclosed herein are non-naturally occurring vesicle comprising a chimeric vesicle localization moiety comprising a surface-and-transmembrane domain of a first vesicle localization moiety and a cytosolic domain of a second vesicle localization moiety, the method of making said vesicle and uses thereof.

Abstract: The present disclosure provides a method for freeze-drying cells in a hydrogel comprising nanofibrillar cellulose, the method comprising providing a hydrogel comprising nanofibrillar cellulose, providing cells, combining the cells and the hydrogel comprising nanofibrillar cellulose to form a cell system, and freeze drying the cell system to obtain dried cells in a hydrogel comprising nanofibrillar cellulose. The present disclosure also provides a freeze-dried hydrogel comprising nanofibrillar cellulose and cells.

Abstract: The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include an ionizable lipid, a phospholipid, a first sterol or a tocopherol, and optionally a second sterol different from the first sterol. Nanoparticle compositions further including therapeutic and/or prophylactics such as RNA are useful in the delivery of therapeutic and/or prophylactics to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.

Abstract: An apparatus and corresponding process can be used for producing nanocarriers and or nanoformulations and corresponding process products. The apparatus is characterized by a vertical orientation of the feed conduits leading to active element. The feed conduits are nested within one another and are axially movable in terms of their orientation to one another. The process provides for the mixing of at least two liquid phases with different acidities. The volume flow of the first phase is greater than that of the second phase.

Abstract: A plastic material for extended release of a bio-active agent, the plastic material comprising a structural polymer, at least one bio-active ingredient embedded within the structural polymer as solid islands, a liquid binding material embedded within the structural polymer as granules, and a carrier liquid absorbed within the liquid-absorbent material. The carrier liquid may be sufficiently non-compatible with the structural polymer so that at least a portion of the carrier liquid is released from the liquid-absorbent material through the structural polymer to an outer surface of the plastic material over a period of time, such as a week or more, a month or more, or about three months. The bio-active agent comprised in the at least one bio-active ingredient may be sufficiently soluble in the carrier liquid at room or body temperature so that the carrier liquid released to the outer surface comprises the bio-active agent in solution.

Abstract: A medical fixing brace, wherein at least one surface is provided with a plurality of step holes for mounting snap-fit seats and posts; the thickness of the mesh plate is made thinner at the step holes; and each of the step holes is assembled with some parts of the snap-fit seats and posts. According to the invention, the fixing brace can be used for both the left body and the right body, convenient for the doctor; the product does not absorb water and has no pad structure, so it is quick in drying after bathing, and it is good in comfort for the wearer; any pruritus and dermatitis can be avoided; and the external fixing brace according to the invention can be used for bone support of the upper limb, the neck, the chest, the waist, the lower limb and the like.

Abstract: A chitosan film including ternary metal oxides. In an embodiment, the ternary metal oxides can include tungsten oxide nanoparticles (WO3 NPs), magnesium oxide nanoparticles (MgO NPs), and a graphene oxide (GO) layer. In an embodiment the chitosan film is porous. The chitosan film including ternary metal oxides can be used as a wound dressing for the clinical management of bacterially infected wounds.

Abstract: Various embodiments disclosed relate to methods and compositions for antimicrobial treatment. In various embodiments, the present invention provides a method of antimicrobial treatment. The method includes at least one of exposing at least one microbe to a magnetic field, and contacting the at least one microbe with at least one nanoparticle including iron.

Abstract: A method for producing a protein composition containing a protein (A), a radical scavenger (RS), and at least one hydrogen-bond-formable compound (HC) selected from the group consisting of amino acids, peptides, and proteins other than the protein (A). The method including a sterilization step of radiosterilizing an unsterilized protein composition, wherein the unsterilized protein composition contains the protein (A), the radical scavenger (RS), and the hydrogen-bond-formable compound (HC), the protein (A) contains at least one functional group selected from the group consisting of sulfide, amide, hydroxyl, amino, and carboxyl groups, the hydrogen-bond-formable compound (HC) contains at least one functional group selected from the group consisting of sulfide, amide, hydroxyl, amino, and carboxyl groups, the at least one functional group in the protein (A) is capable of binding to the at least one functional group in the hydrogen-bond-formable compound (HC) via a hydrogen bond.

Abstract: A system and method for safe decontamination of a vehicle cabin while passengers can be present are disclosed that uses and/or has at least one data storage, at least one processor, at least one infrared (“IR”) sensor, and at least one ultraviolet (“UV”) emitter having a beam steering module. At least one contaminated area in the vehicle cabin is tracked using IR sensor data from the IR sensor. It is determined if there's a direct line of sight between the UV emitter and the at least one contaminated area. If so, UV emitter is activated to target the at least one contaminated area and blocking UV illumination on non-contaminated areas of the vehicle cabin and areas temporarily covered by a passenger.

Abstract: A sanitization system for an aircraft may comprise: a power source; and a plurality of sanitizers in electrical communication with the power source, each sanitizer in the plurality of sanitizers configured to emit ultraviolet radiation having an average wavelength between 200 and 230 nm, the power source configured to provide power to each sanitizer in the plurality of sanitizers in succession during an occupied flight of the aircraft.

Abstract: This embodiment relates to a button module having a sterilization function. The button module according to one aspect comprises: a cover including an opening; a housing being coupled to the cover; a button body disposed inside the housing, including a first body and a second body selectively exposed to the outside through the opening; a rotation shaft for rotating the button body; a printed circuit board disposed at a rear side of the button body, the printed circuit board including a switch and a germicidal lamp irradiating light toward the button body; and an elastic member disposed between the rotation shaft and the first body and between the rotation shaft and the second body.

Abstract: Disclosed herein are biological indicators suitable for use in a liquid-chemical sterilization process that may be conducted by an automated endoscope reprocessor. The biological indicator may include one or more ports for introducing and removing a liquid-chemical sterilant therefrom. The biological indicators may include features, such as a declivity leading to a port opening or a pipette, that may assist in transferring the liquid-chemical sterilant. The system may additionally include a holder having features that facilitate use of the system and biological indicators.

Abstract: One aspect of the invention provides a method of treating a chronic wound including administering to the wound at least one agent from a delivery system wherein the agent induces sequential conversion of a first population of wound macrophages in the wound to M2A macrophages and a second population of wound macrophages to M2C macrophages. The sequential conversion of the wound macrophages promotes tissue remodeling.

Abstract: The present invention provides an artificial dressing and a use of the artificial dressing for promoting wound healing. The artificial dressing includes a gelatin and a fungal extract.

Abstract: The present application provides an orthopedic implant or a part thereof, comprising biodegradable magnesium alloy comprising magnesium and Ca in the range of 0.550-0.700 wt %, Zn in the range of 0.400-0.700 wt %, and Fe 50 ppm or less, the biodegradable magnesium alloy consisting of two phases comprising a first phase comprising magnesium and Zn and a second phase less noble than the first phase, the second phase comprising Mg2Ca precipitates larger than nano-sized. The present application also provides a method for preparing the biodegradable magnesium alloy, a method for preparing the orthopedic implant or the part thereof, and a method for treating a subject in need of therapy for a medical condition of a bone.

Abstract: A method of preparing an inorganic binder for medical use according to an embodiment of the present disclosure includes preparing a starting material using a-TCP powder and phosphate powder each of which has a predetermined particle size, producing a paste having a predetermined viscosity that is suitable for formation of a molded article having a predetermined shape by homogeneously mixing the starting material, adding water or saline to the homogeneously mixed starting material, and kneading the resulting mixture, subjecting the molded article to hydration reaction, and washing and drying the molded article having undergone the hydration reaction to obtain an inorganic binder containing OCP and HA crystal phases.

Abstract: A bone-regeneration material that contains calcium phosphate particles in a biodegradable fiber containing PLGA by using electrospinning. A PLGA resin is heated in a kneader to soften until the viscosity of the resin becomes 102 to 107 Pa·s. A powder of calcium phosphate fine particles is added and mixed with the softened PLGA resin, while the blade of the kneader rotates. The mixture is kneaded by applying thermal and mechanical energy to the mixture through the continuous rotation of the blade of the kneader in the heated state, and aggregations of the calcium phosphate fine particles are disintegrated to prepare a composite in which the calcium phosphate fine particles are dispersed in the PLGA resin. The composite is dissolved in a solvent to prepare a spinning solution. Electrospinning is performed on the spinning solution to manufacture biodegradable fibers having therein the calcium phosphate fine particles substantially uniformly dispersed.

Abstract: The present disclosure describes the use of immune modulators to promote nerve growth and regeneration, particularly in the context of nerve deficit stemming from trauma and disease. In particular, the disclosure provides for the use of CXCR4 antagonsists, STAT3 activators, and an agent that increase nitric oxide, alone or in combination, to treat nerve deficit conditions.

Abstract: The present invention relates to a composition comprising stem cells, a cell culture medium and a polyacrylamide hydrogel (PAAG), wherein the PAAG contains less than 0.02% Wmonomer/Wtotal PAAG] of a N-hydroxyethyl acrylamide (HEA) side chain. The invention also relates to the process of making the composition. In particular, the present invention relates to the composition, wherein the composition is administered by injection and wherein it is used in medicine, in particular for use in prevention and/or treatment of e.g. tendon injury in a mammal, arthritis in a mammal or arthropathy in a mammal. Tendon injury, arthritis or arthropathy may occur in a human, a racing animal or a companion animal.

Abstract: Novel, lubricious coatings for medical devices are disclosed. The coatings provide improved lubricity and durability and are readily applied in coating processes a low temperatures that do not deform the device. The present invention is also directed to a novel platinum catalyst for use in such coatings. The catalyst provides for rapid curing, while inhibiting cross-linking at ambient temperatures, thereby improving the production pot life of the coatings.

Abstract: Disclosed is a method for producing a medical instrument having a lubricating layer (a coating layer) exhibiting excellent durability (particularly, sliding durability). The method for producing a medical instrument is a method for producing a medical instrument having a base layer, and a lubricating layer that is carried on at least a part of the base layer. The method for producing a medical instrument also includes applying, to the base layer, a solution containing a block copolymer having a structural unit (A) derived from a reactive monomer having an epoxy group and a structural unit (B) derived from a hydrophilic monomer, an alkylammonium salt having 8 to 24 carbon atoms, and a solvent; and washing off the solution applied to the base layer.

Abstract: A tissue adhesion prevention hydrogel is provided and engineered with essential features for maintaining separation between tissues and organs in any part of the body, thus preventing adhesion formation, are their shear-thinning, viscoelasticity, and rapid self-healing. A method of using the tissue adhesion prevention hydrogel for tissue adhesion prevention is also provided. A method of interposing the tissue adhesion prevention in between tissue layers for tissue adhesion prevention is further provided.

Abstract: Disclosed herein is a method of using a biomaterial for treating a condition. The biomaterial can comprise a plurality of geometric elements. Implantation of a biomaterial disclosed herein into a subject can treat, for example, cancer.

Abstract: Drug eluting stents, methods of making, using, and verifying long-term stability of the drug eluting stents, and methods for predicting long term stent efficacy and patient safety after implantation of a drug eluting stent are disclosured. In one embodiment, a drug eluting stent may include a stent framework; a drug-containing layer; a drug embedded in the drug-containing layer; and a biocompatible base layer disposed over the stent framework and supporting the drug-containing layer. The drug-containing layer may have an uneven coating thickness. In addition or in alternative, the drug-containing layer may be configured to significantly dissolve/dissipate/disappear between 45 days and 60 days after stent implantation. Stents may reduce, minimize, or eliminate patient risks associated with the implantation of a stent, including, for example, restenosis, thrombosis, and/or MACE.

Abstract: The exemplary systems and methods may generate treatment records for extracorporeal blood treatments. The treatment records may include a plurality of values of various parameters. The various parameters may include a compulsory set of parameters that are preset, a dependent set of parameters that a dependent on one or more of a selected treatment and a system configuration, and a discretionary set of parameters that are selected by a user.

Abstract: A system and a solution-preparation-determining apparatus which determines whether additional preparation of an undiluted dialysate solution is necessary.

Abstract: A medical device, such as a hemodialysis machine or a peritoneal dialysis machine, is provided with control commands in a secure manner based on the commands being detected on a separate control component. The control commands are detected and thereupon a message is generated which contains a request to activate an operating element. Only if the indicated operating element has been activated is the control command forwarded to a dialysis machine for execution.

Abstract: The present invention discloses a microstructured discrimination device for separating hydrophobic-hydrophilic fluidic composites comprising particulate and/or fluids in a fluid flow. The discrimination is the result of surface energy gradients obtained by physically varying a textured surface and/or by varying surface chemical properties, both of which are spatially graded. Such surfaces discriminate and spatially separate particulate and/or fluids without external energy input. The device of the present invention comprises a platform having bifurcating microchannels arranged radially. The lumenal surfaces of the microchannels may have a surface energy gradient created by varying the periodicity of hierarchically arranged microstructures along a dimension. The surface energy gradient is varied in two regions. In one pre-bifurcation region the surface energy gradient generates a fluid flow.